D-erythro-Sphingosine-d7

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 (Pt 3) :699-703.|[3]Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N, N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172 (2) :683-91.|[4]Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30 (1) :22-7.|[5]Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359 (1-2) :48-56.